Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | VDR | P11473 | 6/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17349973 | 0.91 | VDR (0.34) | ALDH1A1TP53TSHRNPC1RAB9A | |
| SCHEMBL17366110 | 0.90 | VDR (0.35) | MEN1KMT2AALDH1A1GLATP53 | |
| SCHEMBL17051364 | 0.89 | KMT2A (0.33) | MEN1KMT2AALDH1A1GLATP53 | |
| SCHEMBL17345231 | 0.85 | ALDH1A1 (0.37) | ALDH1A1GLATP53TSHRNPC1 | |
| SCHEMBL17350000 | 0.85 | ALDH1A1 (0.37) | ALDH1A1GLATP53TSHRNPC1 | |
| SCHEMBL17045647 | 0.82 | MEN1 (0.49) | MEN1KMT2AALDH1A1GLATP53 | |
| SCHEMBL17345237 | 0.80 | ALDH1A1 (0.32) | ALDH1A1GLATP53TSHRNPC1 | |
| SCHEMBL17055462 | 0.80 | MEN1 (0.32) | MEN1KMT2AVDR | |
| SCHEMBL17055365 | 0.76 | MEN1 (0.42) | MEN1KMT2AALDH1A1GLATP53 | |
| SCHEMBL17345238 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2960245-B1 | EPOXY COMPOUND HAVING ALKOXYSILYL GROUP, METHOD FOR MANUFACTURING SAME, COMPOSITION AND CURED PRODUCT INCLUDING SAME, AND USE THEREOF | KOREA INST IND TECH (KR) | 2019-07-31 | — | — | EP | disclosed |
| US-9732182-B2 | Epoxy compound having alkoxysilyl group, method of preparing the same, composition and cured product comprising the same, and use thereof | KOREA INSTITUTE OF INDUSTRIAL TECHNOLOGY (KR) | 2017-08-15 | — | — | US | disclosed |
| US-9732182-B2 | Epoxy compound having alkoxysilyl group, method of preparing the same, composition and cured product comprising the same, and use thereof | KOREA INSTITUTE OF INDUSTRIAL TECHNOLOGY (KR) | 2017-08-15 | — | — | US | disclosed |
| US-20150361211-A1 | EPOXY COMPOUND HAVING ALKOXYSILYL GROUP, METHOD OF PREPARING THE SAME, COMPOSITION AND CURED PRODUCT COMPRISING THE SAME, AND USE THEREOF | KOREA INSTITUTE OF INDUSTRIAL TECHNOLOGY (KR) | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361211-A1 | EPOXY COMPOUND HAVING ALKOXYSILYL GROUP, METHOD OF PREPARING THE SAME, COMPOSITION AND CURED PRODUCT COMPRISING THE SAME, AND USE THEREOF | ESD, PFAS, SCD5 | MEN1 1433/4885KMT2A 1654/4885ALDH1A1 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.